890 F. Supp. 2d 534
D.N.J.2012Background
- Blueberry farms in Hammonton, NJ sue Novartis over AG600, a Diazinon insecticide, allegedly causing plant and fruit damage when tank-mixed with fungicides; plaintiffs used prior Novartis products (50 WP, AG500) similarly without harm.
- Novartis marketed AG600 as safer/effective and allegedly knew of hidden surfactant in AG600 that caused plant injury when mixed with fungicides.
- Plaintiffs allege core harm was from AG600 causing damage to plants/fruit, with misrepresentations about safety; they also allege CFA violations.
- PLA governs product-harm actions and may subsume non-PLA claims; this case concerns whether fraud-based claims are subsumed by PLA.
- Court previously addressed multiple rounds of motion practice and appeals; Counts IV (negligent misrepresentation/fraud) and VII (CFA) are now under scrutiny for subsumption by the PLA.
- Plaintiffs’ Fourth Amended Complaint focuses on AG600-induced damage and alleged misrepresentations; the core issue is harm to plants/land from AG600.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether CFA/common-law misrepresentation claims are subsumed by the PLA | Plaintiffs contend CFA claims are distinct and not subsumed | Novartis argues PLA governs any product-harm claims and subsumes CFA and misrepresentation | Yes; claims subsumed and dismissed |
| Whether the core issue is harm caused by a product rather than misrepresentation | Plaintiffs argue misrepresentation is separable from product harm | Court should treat core issue as product-harm under PLA | Core issue is product-harm; subsumed by PLA |
| Whether Wendling/Lee support non-subsumption of CFA claims | Plaintiffs rely on Wendling/Lee to avoid subsumption | Wendling/Lee do not control here; PLA governs when product harm is core | Not controlling; PLA subsumes CFA here |
Key Cases Cited
- Lead Paint Litigation, 924 A.2d 484 (N.J. 2007) (PLA governs product-harm; CFA not independent when product injuries alleged)
- Sinclair v. Merck & Co., 948 A.2d 587 (N.J. 2008) (PLA paramount over CFA for harm caused by a product)
- McDarby v. Merck & Co., 949 A.2d 223 (N.J. Super. Ct. App. Div. 2008) (CFA claims subsumed by PLA when core issue is failure to warn about product dangers)
- Bailey v. Wyeth, Inc., 37 A.3d 549 (N.J. Super. Ct. Law Div. 2008) (CFA and misrepresentation claims subsumed by PLA; no extra treble-damages relief under CFA for product-harm cases)
- Repola v. Morbark Indus., Inc., 934 F.2d 483 (3d Cir. 1991) (Third Circuit predicted NJPLA subsumes common-law product liability claims; PLA exclusive remedy for product harm)
- Lee v. Carter-Reed Co., 4 A.3d 561 (N.J. 2010) (CFA case; not addressing PLA subsumption; not controlling here)